The ups and downs of life as a small-cap med-tech company go on for TearLab (TEAR).
There's still plenty of controversy regarding this name, not the least
of which is a mixed bag of clinical papers on the company's osmolarity
system, but strong system bookings certainly haven't done the stock any
harm.
Most recently, though, the company announced the appointment of Seph Jensen, a long-time Alcon (part of Novartis (NVS))
veteran, as the company's new President and COO. Not only can Jensen
bring experience on the device side of ophthalmology to the company and
help the company appropriately build its sales/marketing efforts, but
the addition of an industry veteran from a well-known company helps the
image of TearLab as well.
Please follow this link to continue:
TearLab Builds Its Bench
Showing posts with label Alcon. Show all posts
Showing posts with label Alcon. Show all posts
Wednesday, October 2, 2013
Seeking Alpha: TearLab Builds Its Bench
Labels:
Alcon,
Novartis,
Seeking Alpha,
TearLab
Wednesday, December 12, 2012
Seeking Alpha: Is Bausch & Lomb The Next Multibillion-Dollar Deal?
Could another major med-tech M&A transaction be on the way?
Rumors are now in flight that large private equity group Warburg Pincus is ready to sell its large eye care business Bausch & Lomb. While recent reports suggest that Warburg would prefer an outright sale at this point, it sounds like an IPO could be in the works as a back-up plan. But the larger question for investors is whether there are any motivated bidders out there likely to meet Warburg's price target.
Please read more here:
Is Bausch & Lomb The Next Multibillion-Dollar Deal?
Rumors are now in flight that large private equity group Warburg Pincus is ready to sell its large eye care business Bausch & Lomb. While recent reports suggest that Warburg would prefer an outright sale at this point, it sounds like an IPO could be in the works as a back-up plan. But the larger question for investors is whether there are any motivated bidders out there likely to meet Warburg's price target.
Please read more here:
Is Bausch & Lomb The Next Multibillion-Dollar Deal?
Labels:
Abbott Labs,
Alcon,
Bausch Lomb,
GlaxoSmithKline,
Johnson Johnson,
Merck,
Novartis,
Roche,
Sanofi,
Seeking Alpha,
Warburg Pincus
Tuesday, April 5, 2011
Seeking Alpha: The Incredible Shrinking Eye Care Sector
Tuesday's announcement from Merck (NYSE: MRK) that is acquiring Inspire Pharmaceuticals (Nasdaq: ISPH) is interesting on a couple of fronts. It's interesting for the multiple that Merck is paying and it is a good exit for Inspire shareholders. It is also interesting because it leaves so few publicly traded stocks in the eye care sector.
A Fair Deal For A Troubled Company
Merck is offering $5 in cash for each share of Inspire Pharmaceuticals, for a total deal value of $430 million. Although this price was a 26% premium to Monday's closing price, it was only half of where the stock was trading as recently as December, and that's a big part of why the company is taking the deal.
Inspire's shares got crushed when the company's drug candidate for cystic fibrosis (denufosol tetrasodium) failed in a Phase 3 study and the company abandoned the program. Add that failure to the prior Phase 3 failure of Prolacria in dry eye and the company was left with a very thin pipeline – a low-potential follow-on indication for AzaSite in blepharitis and some early-stage glaucoma compounds (likely at least six or seven years from marketability).
To read the full piece, please go here:
The Incredible Shrinking Eye Care Sector
A Fair Deal For A Troubled Company
Merck is offering $5 in cash for each share of Inspire Pharmaceuticals, for a total deal value of $430 million. Although this price was a 26% premium to Monday's closing price, it was only half of where the stock was trading as recently as December, and that's a big part of why the company is taking the deal.
Inspire's shares got crushed when the company's drug candidate for cystic fibrosis (denufosol tetrasodium) failed in a Phase 3 study and the company abandoned the program. Add that failure to the prior Phase 3 failure of Prolacria in dry eye and the company was left with a very thin pipeline – a low-potential follow-on indication for AzaSite in blepharitis and some early-stage glaucoma compounds (likely at least six or seven years from marketability).
To read the full piece, please go here:
The Incredible Shrinking Eye Care Sector
Thursday, December 16, 2010
Novartis Brings Alcon Into The Fold
Novartis (NYSE:NVS) shareholders should not begrudge the fact that their management team was willing to put the screws to Alcon's (NYSE:ACL) minority shareholders in the hopes of finishing up the acquisition of this significant eye-care franchise at as low a price as possible. That said, Novartis should also be applauded for seeing reason and finally deciding to offer a fair deal to those Alcon shareholders. Shareholders of companies like Lilly (NYSE:LLY), Bristol Myers (NYSE:BMY) and Sanofi-aventis (NYSE:SNY) might wonder why their management teams are not being similarly aggressive.
The (Successful) End of the Deal
Whether it was a desire to simply finish the deal or the prospect of fighting the Alcon board in court (essentially paying to fight itself, as Novartis already controlled about 77% of the stock), Novartis abandoned its attempt to jerk around the minority shareholders and offer a fair price. To that end, Novartis announced an agreement whereby it will acquire the rest of Alcon for $168 per share. Novartis intends to do the deal with stock, but will supplement it with cash as needed to maintain the deal value. Simultaneously, the company will restart its multi-billion dollar buyback program to neutralize the impact of these extra shares.
Please click below for the full piece:
http://stocks.investopedia. com/stock-analysis/2010/ Novartis-Brings-Alcon-Into- The-Fold-ACL-NVS-AGN-ISTA-LLY- SNY-BMY1216.aspx
The (Successful) End of the Deal
Whether it was a desire to simply finish the deal or the prospect of fighting the Alcon board in court (essentially paying to fight itself, as Novartis already controlled about 77% of the stock), Novartis abandoned its attempt to jerk around the minority shareholders and offer a fair price. To that end, Novartis announced an agreement whereby it will acquire the rest of Alcon for $168 per share. Novartis intends to do the deal with stock, but will supplement it with cash as needed to maintain the deal value. Simultaneously, the company will restart its multi-billion dollar buyback program to neutralize the impact of these extra shares.
Please click below for the full piece:
http://stocks.investopedia.
Labels:
Alcon,
Allergan,
Bristol-Myers Squibb,
ISTA Pharmaceuticals,
Lilly,
Nestle,
Novartis,
Sanofi Aventis
Monday, July 19, 2010
Novartis On The Right Track
It has taken longer than some analysts predicted, but it looks like Novartis' (NYSE:NVS) strategy is finally paying off. It was not that long ago that Novartis looked like a just another floundering drug company with a weak pipeline. When the Sandoz acquisition failed to immediately produce results, more people wrote off the company and sold the stock. Now, though, Novartis looks like one of the more dynamic names in big-cap pharma.
The Quarter That Was
Novartis produced a very good June quarter. Sales were up 12% to nearly $12 billion, as pharmaceutical sales rose 8% and Sandoz (the company's generics business) saw revenue rise 13%. Oncology and cardiology drugs make more than half of the company's pharmaceutical revenue base, and these were up 11% and 8%, respectively, as major contributors like Diovan and Gleevec continue to grow.
For the complete piece, go to:
http://stocks.investopedia. com/stock-analysis/2010/ Novartis-On-The-Right-Track- NVS-AZN-BMY-PFE-ACL-LLY- ABT0719.aspx
The Quarter That Was
Novartis produced a very good June quarter. Sales were up 12% to nearly $12 billion, as pharmaceutical sales rose 8% and Sandoz (the company's generics business) saw revenue rise 13%. Oncology and cardiology drugs make more than half of the company's pharmaceutical revenue base, and these were up 11% and 8%, respectively, as major contributors like Diovan and Gleevec continue to grow.
For the complete piece, go to:
http://stocks.investopedia.
Labels:
Abbott Labs,
Alcon,
AstraZeneca,
Bristol-Myers Squibb,
Lilly,
Nestle,
Novartis,
Pfizer,
Roche
Subscribe to:
Posts (Atom)